BioMérieux: Oddo BHF upgrades stock & raises TP

(CercleFinance.com) - Oddo BHF has upgraded its rating on bioMérieux shares from 'neutral' to 'outperform', with a target price raised from E113 to E132.


bioMérieux announces that it has completed the acquisition of the Norwegian start-up Spinchip Diagnostics, specialising in in vitro immunoassay diagnostics, for an enterprise value of E138m, after initially acquiring a 20% stake.

This acquisition will strengthen SpotFire's offering with tests targeting cardiac pathologies from 2026, with ramp-up planned by the end of 2028.

In addition, the biotech company has unveiled an update on its installed base in Q4 2024: net installations include +500 units for BioFire and +900 for SpotFire, reaching a total of 3,000 units for SpotFire since its launch a year ago, confirming strong acceleration and planned targets.

Oddo BHF says that the time for delivery has come: the timing, to play the growth and OM appreciation as described by the GO 2028 tarhets, seems to us to be getting better again, particularly regarding 2025 and beyond.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.